Unpulsed DCs

Phase 2Biologic

MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Unpulsed DCs is one of 4 biologic programs targeting GBM. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GBMActive, not recruiting

GBMPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in GBM

#DrugCompanyPhaseTrials

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

3 2

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

1 3

Varlilumab

NNational Cancer Institute (NCI)

Phase 2

1 4

Unpulsed DCs

MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

GBM2 trials

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruiting·—·Phase 2·NCT03688178·43 enrolled

DC Migration Study for Newly-Diagnosed GBM

Completed·MMustafa Khasraw, MBChB, MD, FRCP, FRACP·Phase 2·NCT02366728·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Unpulsed DCs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Unpulsed DCs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Unpulsed DCs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mustafa Khasraw, MBChB, MD, FRCP, FRACP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Unpulsed DCs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

GBM2 trials

References

Drug Info

Quick Facts

Related News